24/7 Market News Snapshot 29 July, 2025 – Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

July 29, 2025

DENVER, Colo., 29 July, 2025 (www.247marketnews.com) – (NASDAQ:ACRS) are discussed in this article.
Aclaris Therapeutics, Inc. is experiencing a notable uptick in its share price, which rose to $1.976, reflecting a significant increase of 17.62% from the previous session. The stock opened at $1.71 and has registered a trading volume of 3.69 million shares, indicating a growing interest and activity among investors. This surge may be attributed to the company’s recent announcement concerning top-line results from its Phase 2a clinical trial of ATI-2138, an oral covalent inhibitor designed to tackle immuno-inflammatory diseases.

The trial focused on 14 patients suffering from moderate-to-severe atopic dermatitis and demonstrated promising outcomes, affirming the compound’s favorable tolerability and efficacy benchmarks that align with established therapies. CEO Dr. Neal Walker expressed his pride in the results, emphasizing the clinical implications of achieving the study’s objectives, particularly concerning safety and efficacy measures. Impressively, participants noted an average reduction of 60.5% in the Eczema Area and Severity Index (EASI) score over the 12-week period.

Further analysis revealed significant modulation of inflammatory pathways related to ITK inhibition, underscoring the therapeutic potential of ATI-2138 in addressing immune system dysfunctions associated with atopic dermatitis. The company aims to expand the development of ATI-2138 not only for atopic dermatitis but also for conditions like alopecia areata.

Following these encouraging results, Aclaris is positioning itself for future clinical advancements, with intentions to advance research on next-generation ITK inhibitors and potentially file Investigational New Drug (IND) applications as early as 2026. These developments solidify Aclaris’ role as a leading contender in delivering innovative treatments for complex immunological challenges and highlight the company’s ongoing commitment to addressing unmet medical needs.

Related news for (ACRS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.